Milad Shahsavari
Research Subjects
Milad Shahsavari has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
- Farzaneh Hosseini
Department of Microbiology, NT.C., Islamic Azad University, Tehran, Iran
2 shared publications - Mohamad Reza Razavi
Pasteur Institute of Iran
2 shared publications - Sedigheh Arbabian
Department of Biology, NT.C., Islamic Azad University, Tehran, Iran
2 shared publications
Latest Publications
- 28 February 2025
- Published by Elsevier in Gene Reports
- Vol. 39
LncRNAs PVT1, HULC, and HOTTIP: A promising biomarker trio for diffuse large B-cell lymphoma
- 28 February 2025
- Published by Elsevier in Gene Reports
- Vol. 39
LncRNAs PVT1, HULC, and HOTTIP: A promising biomarker trio for diffuse large B-cell lymphoma
- Open Access
The PVT1, HULC, and HOTTIP expression changes due to treatment in Diffuse Large B-cell lymphoma
Diffuse large B-cell lymphoma is the most common histological subtype of non-Hodgkin’s lymphomas. It is an aggressive malignancy that displays great heterogeneity in morphology, genetics, biological behavior and treatment response owing to chromatin remodeling and epigenetics. Bioinformatic-based approaches were used to understand the possible signaling pathways of the three lncRNAs PVT1 , HULC , and HOTTIP . Furthermore, their expression levels were quantitatively evaluated in 100 patients before and after the treatment. The results revealed that gene expression was significantly upregulated in PVT1 , HULC , and HOTTIP by 7.39±8.48-, 5.924±7.536-, and 4.137±5.863 fold, respectively, relative to normal cases. Post-treatment measurement of lncRNA expression indicated that PVT1 and HOTTIP were significantly downregulated. Interestingly, the expression levels of PVT1 , HULC , and HOTTIP were significantly higher in DLBCL patients aged > 60 years than in those aged < 60 years. In addition, there was a significant positive correlation between HULC and HOTTIP expression. The analysis of overexpressed lncRNA-miRNA interaction indicated different deregulated miRNA targets and the protein targets of upregulated lncRNAs are mainly with histone modification, DNA methylation/demethylation, and protein methyltransferase activity. Summary blurb: The lncRNAs PVT1 , HULC , and HOTTIP expression is significantly upregulated before treatment and reduce to normal level after treatment. It can be used as diagnostic marker or prognostic means especially in Relapsed/refractory DLBCL.
Open AccessThe PVT1, HULC, and HOTTIP expression changes due to treatment in Diffuse Large B-cell lymphoma
Diffuse large B-cell lymphoma is the most common histological subtype of non-Hodgkin’s lymphomas. It is an aggressive malignancy that displays great heterogeneity in morphology, genetics, biological behavior and treatment response owing to chromatin remodeling and epigenetics. Bioinformatic-based approaches were used to understand the possible signaling pathways of the three lncRNAs PVT1 , HULC , and HOTTIP . Furthermore, their expression levels were quantitatively evaluated in 100 patients before and after the treatment. The results revealed that gene expression was significantly upregulated in PVT1 , HULC , and HOTTIP by 7.39±8.48-, 5.924±7.536-, and 4.137±5.863 fold, respectively, relative to normal cases. Post-treatment measurement of lncRNA expression indicated that PVT1 and HOTTIP were significantly downregulated. Interestingly, the expression levels of PVT1 , HULC , and HOTTIP were significantly higher in DLBCL patients aged > 60 years than in those aged < 60 years. In addition, there was a significant positive correlation between HULC and HOTTIP expression. The analysis of overexpressed lncRNA-miRNA interaction indicated different deregulated miRNA targets and the protein targets of upregulated lncRNAs are mainly with histone modification, DNA methylation/demethylation, and protein methyltransferase activity. Summary blurb: The lncRNAs PVT1 , HULC , and HOTTIP expression is significantly upregulated before treatment and reduce to normal level after treatment. It can be used as diagnostic marker or prognostic means especially in Relapsed/refractory DLBCL.